BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tsujita R, Tsubota M, Sekiguchi F, Kawabata A. Role of high-mobility group box 1 and its modulation by thrombomodulin/thrombin axis in neuropathic and inflammatory pain. Br J Pharmacol 2021;178:798-812. [PMID: 32374414 DOI: 10.1111/bph.15091] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Kimura H. From neurotransmission to neuronal disorders. Br J Pharmacol 2021;178:747-9. [PMID: 33534917 DOI: 10.1111/bph.15354] [Reference Citation Analysis]
2 Tsubota M, Miyazaki T, Ikeda Y, Hayashi Y, Aokiba Y, Tomita S, Sekiguchi F, Wang D, Nishibori M, Kawabata A. Caspase-Dependent HMGB1 Release from Macrophages Participates in Peripheral Neuropathy Caused by Bortezomib, a Proteasome-Inhibiting Chemotherapeutic Agent, in Mice. Cells 2021;10:2550. [PMID: 34685531 DOI: 10.3390/cells10102550] [Reference Citation Analysis]
3 Ueda H. Pathogenic mechanisms of lipid mediator lysophosphatidic acid in chronic pain. Prog Lipid Res 2021;81:101079. [PMID: 33259854 DOI: 10.1016/j.plipres.2020.101079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 Ye S, Ma F, Mahmood DFD, Meyer-siegler KL, Leng L, Bucala R, Vera PL. Bladder Oxidative Stress and HMGB1 Release Contribute to PAR4-Mediated Bladder Pain in Mice. Front Syst Neurosci 2022;16:882493. [DOI: 10.3389/fnsys.2022.882493] [Reference Citation Analysis]
5 Sato F, Nakamura Y, Ma S, Kochi T, Hisaoka-Nakashima K, Wang D, Liu K, Wake H, Nishibori M, Morioka N. Central high mobility group box-1 induces mechanical hypersensitivity with spinal microglial activation in a mouse model of hemi-Parkinson's disease. Biomed Pharmacother 2022;145:112479. [PMID: 34915668 DOI: 10.1016/j.biopha.2021.112479] [Reference Citation Analysis]
6 Domoto R, Sekiguchi F, Kamaguchi R, Iemura M, Yamanishi H, Tsubota M, Wang D, Nishibori M, Kawabata A. Role of neuron-derived ATP in paclitaxel-induced HMGB1 release from macrophages and peripheral neuropathy. J Pharmacol Sci 2022;148:156-61. [PMID: 34924121 DOI: 10.1016/j.jphs.2021.11.003] [Reference Citation Analysis]
7 Domoto R, Sekiguchi F, Tsubota M, Kawabata A. Macrophage as a Peripheral Pain Regulator. Cells 2021;10:1881. [PMID: 34440650 DOI: 10.3390/cells10081881] [Reference Citation Analysis]
8 Sekiguchi F, Kawabata A. Role of HMGB1 in Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci 2020;22:E367. [PMID: 33396481 DOI: 10.3390/ijms22010367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Miyamoto T, Hiramoto S, Kanto A, Tsubota M, Fujitani M, Fukuyama H, Hatanaka S, Sekiguchi F, Koizumi Y, Kawabata A. Estrogen decline is a risk factor for paclitaxel-induced peripheral neuropathy: Clinical evidence supported by a preclinical study. J Pharmacol Sci 2021;146:49-57. [PMID: 33858655 DOI: 10.1016/j.jphs.2021.03.001] [Reference Citation Analysis]
10 Meng L, Huang J, Qiu F, Shan X, Chen L, Sun S, Wang Y, Yang J. Peripheral Neuropathy During Concomitant Administration of Proteasome Inhibitors and Factor Xa Inhibitors: Identifying the Likelihood of Drug-Drug Interactions. Front Pharmacol 2022;13:757415. [DOI: 10.3389/fphar.2022.757415] [Reference Citation Analysis]
11 Deng C, Xie Y, Liu Y, Li Y, Xiao Y. Aromatherapy Plus Music Therapy Improve Pain Intensity and Anxiety Scores in Patients With Breast Cancer During Perioperative Periods: A Randomized Controlled Trial. Clin Breast Cancer 2021:S1526-8209(21)00134-8. [PMID: 34134947 DOI: 10.1016/j.clbc.2021.05.006] [Reference Citation Analysis]
12 Totoki T, Ito T, Yamada S, Honda G, Hattori T, Maruyama I. Specific detection of high mobility group box 1 degradation product with a novel ELISA. Mol Med 2021;27:59. [PMID: 34107884 DOI: 10.1186/s10020-021-00323-1] [Reference Citation Analysis]
13 Miyamoto T, Domoto R, Sekiguchi F, Kamaguchi R, Nishimura R, Matsuno M, Tsubota M, Fujitani M, Hatanaka S, Koizumi Y, Wang D, Nishibori M, Kawabata A. Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies. Journal of Pharmacological Sciences 2022. [DOI: 10.1016/j.jphs.2022.01.006] [Reference Citation Analysis]